Ocular Therapeutix Newsroom

Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $21

Futu NewsDec 6 01:35

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Baxter International (BAX) and Ocular Therapeutix (OCUL)

TipRanksDec 5 23:13

Ocular Therapeutix Analyst Ratings

BenzingaDec 3 19:34

H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15

Futu NewsDec 3 19:31

Promising Outlook for Ocular Therapeutix: Buy Rating Supported by Strong Market Demand and Financial Valuation

TipRanksDec 3 19:22

Scotiabank Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $22

Futu NewsNov 15 21:35

Ocular Therapeutix (OCUL) Gets a Buy From Scotiabank

TipRanksNov 15 20:49

H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $15

Futu NewsNov 15 20:33

Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 15 20:11

BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $18

Futu NewsNov 15 18:34

TD Cowen Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $14

Futu NewsNov 15 00:31

Ocular Therapeutix's Clinical Progress and Strategic Trials Drive Buy Rating

TipRanksNov 14 23:48

Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15

Futu NewsOct 22 19:31

Piper Sandler Remains a Buy on Ocular Therapeutix (OCUL)

TipRanksOct 22 18:57

Baird Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $17

Futu NewsOct 17 23:31

Ocular Therapeutix Price Target Announced at $22.00/Share by Scotiabank

Dow JonesOct 16 22:14

Ocular Therapeutix Analyst Ratings

BenzingaOct 16 18:52

H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $14

Futu NewsOct 16 18:31

BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15

Futu NewsOct 16 17:36

Buy Rating on Ocular Therapeutix: Accelerated Phase 3 Trial Enrollment and Promising 2025 Outlook

TipRanksOct 16 16:57